Ulrich Henning
Department of Biochemistry, Instituto de Química, Universidade de São Paulo, Caixa Postal 26077, São Paulo 05513-970, Brazil.
Med Chem. 2005 Mar;1(2):199-208. doi: 10.2174/1573406053175274.
The SELEX technique (systematic evolution of ligands by exponential enrichment) is a combinatorial library approach in which DNA or RNA molecules are selected by their ability to bind their protein targets with high affinity and specificity. The isolated molecules are referred to as aptamers (from aptus = Latin "to fit"). First, RNA and DNA aptamers were identified that bind to proteins naturally interacting with nucleic acids, or to small organic molecules such as ATP. In the following years, the use of the SELEX technique was extended to isolate oligonucleotide ligands for a wide range of proteins of importance for therapy, and diagnostics. Since these RNA and DNA molecules bind their targets with similar affinities as antibodies, and are able to distinguish between isotypes of an enzyme, aptamers have been also called synthetic antibodies. Recently, the use of in vitro selection methods to isolate protein inhibitors has been extended to complex targets, such as receptors that are only functional in their membrane-bound form, cells, and trypanosomes. RNA aptamers have been expressed in living cells where they inhibit a protein implicated in intracellular signal transduction. The utility of aptamers for in vivo experiments, and diagnostic and therapeutic purposes, is considerably enhanced by introducing chemical modifications into the oligonucleotides to provide resistance against enzymatic degradation in body fluids. Recently, such inhibitors have been evolved for a great variety of targets, including receptors, growth factors, and adhesion molecules implicated in disease. Furthermore, some results were already obtained in animal models and clinical trials.
SELEX技术(指数富集配体系统进化技术)是一种组合文库方法,其中DNA或RNA分子通过其与蛋白质靶标高亲和力和特异性结合的能力进行筛选。分离出的分子被称为适配体(源自拉丁语aptus,意为“适合”)。首先,人们鉴定出了能与天然与核酸相互作用的蛋白质或与ATP等小分子有机化合物结合的RNA和DNA适配体。在接下来的几年里,SELEX技术的应用范围得到了扩展,用于分离针对多种对治疗和诊断具有重要意义的蛋白质的寡核苷酸配体。由于这些RNA和DNA分子与靶标的结合亲和力与抗体相似,并且能够区分酶的不同亚型,适配体也被称为合成抗体。最近,用于分离蛋白质抑制剂的体外筛选方法已扩展到复杂靶标,如仅以膜结合形式发挥功能的受体、细胞和锥虫。RNA适配体已在活细胞中表达,在那里它们抑制一种参与细胞内信号转导的蛋白质。通过对寡核苷酸进行化学修饰以提供对体液中酶促降解的抗性,适配体在体内实验以及诊断和治疗目的方面的效用得到了显著提高。最近,针对包括与疾病相关的受体、生长因子和黏附分子在内的多种靶标,都开发出了这样的抑制剂。此外,在动物模型和临床试验中已经取得了一些成果。